Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors

Jonathan R. Strosberg, George A. Fisher, Al B. Benson, Lowell B. Anthony, Bulent Arslan, John F. Gibbs, Edward Greeno, Renuka V. Iyer, Michelle K. Kim, William J. Maples, Philip A. Philip, Edward M. Wolin, Dasha Cherepanov, Michael S. Broder

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

AIM: To evaluate systemic treatment choices in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors (PNETs) and provide consensus treatment recommendations. METHODS: Systemic treatment options for pancreatic neuroendocrine tumors have expanded in recent years to include somatostatin analogs, angiogenesis inhibitors, inhibitors of mammalian target of rapamycin and cytotoxic agents. At this time, there is little data to guide treatment selection and sequence. We therefore assembled a panel of expert physicians to evaluate systemic treatment choices and provide consensus treatment recommendations. Treatment appropriateness ratings were collected using the RAND/UCLA modified Delphi process. After studying the literature, a multidisciplinary panel of 10 physicians assessed the appropriateness of various medical treatment scenarios on a 1-9 scale. Ratings were done both before and after an extended discussion of the evidence. Quantitative measurements of agreement were made and consensus statements developed from the second round ratings. RESULTS: Specialties represented were medical and surgical oncology, interventional radiology, and gastroenterology. Panelists had practiced for a mean of 15.5 years (range: 6-33). Among 202 rated scenarios, disagreement decreased from 13.2% (26 scenarios) before the face-to-face discussion of evidence to 1% (2) after. In the final ratings, 46.5% (94 scenarios) were rated inappropriate, 21.8% (44) were uncertain, and 30.7% (62) were appropriate. Consensus statements from the scenarios included: (1) it is appropriate to use somatostatin analogs as first line therapy in patients with hormonally functional tumors and may be appropriate in patients who are asymptomatic; (2) it is appropriate to use everolimus, sunitinib, or cytotoxic chemotherapy therapy as first line therapy in patients with symptomatic or progressive tumors; and (3) beyond first line, these same agents can be used. In patients with uncontrolled secretory symptoms, octreotide LAR doses can be titrated up to 60 mg every 4 wk or up to 40 mg every 3 or 4 wk. CONCLUSION: Using the Delphi process allowed physician experts to systematically obtain a consensus on the appropriateness of a variety of medical therapies in patients with PNETs.

Original languageEnglish (US)
Pages (from-to)2450-2459
Number of pages10
JournalWorld Journal of Gastroenterology
Volume21
Issue number8
DOIs
StatePublished - Feb 28 2015
Externally publishedYes

Fingerprint

Neuroendocrine Tumors
Therapeutics
Somatostatin
Physicians
Interventional Radiology
Angiogenesis Inhibitors
Octreotide
Medical Oncology
Cytotoxins
Gastroenterology
Sirolimus
Neoplasms

Keywords

  • Consensus
  • Delphi technique
  • Expert testimony
  • Grade 1
  • Grade 2
  • Intermediate tumors
  • Low tumors
  • Neuroendocrine carcinomas
  • Neuroendocrine tumors
  • Pancreatic neoplasms
  • Treatment
  • Unresectable
  • Well-differentiated

ASJC Scopus subject areas

  • Gastroenterology
  • Medicine(all)

Cite this

Strosberg, J. R., Fisher, G. A., Benson, A. B., Anthony, L. B., Arslan, B., Gibbs, J. F., ... Broder, M. S. (2015). Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors. World Journal of Gastroenterology, 21(8), 2450-2459. https://doi.org/10.3748/wjg.v21.i8.2450

Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors. / Strosberg, Jonathan R.; Fisher, George A.; Benson, Al B.; Anthony, Lowell B.; Arslan, Bulent; Gibbs, John F.; Greeno, Edward; Iyer, Renuka V.; Kim, Michelle K.; Maples, William J.; Philip, Philip A.; Wolin, Edward M.; Cherepanov, Dasha; Broder, Michael S.

In: World Journal of Gastroenterology, Vol. 21, No. 8, 28.02.2015, p. 2450-2459.

Research output: Contribution to journalArticle

Strosberg, JR, Fisher, GA, Benson, AB, Anthony, LB, Arslan, B, Gibbs, JF, Greeno, E, Iyer, RV, Kim, MK, Maples, WJ, Philip, PA, Wolin, EM, Cherepanov, D & Broder, MS 2015, 'Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors', World Journal of Gastroenterology, vol. 21, no. 8, pp. 2450-2459. https://doi.org/10.3748/wjg.v21.i8.2450
Strosberg, Jonathan R. ; Fisher, George A. ; Benson, Al B. ; Anthony, Lowell B. ; Arslan, Bulent ; Gibbs, John F. ; Greeno, Edward ; Iyer, Renuka V. ; Kim, Michelle K. ; Maples, William J. ; Philip, Philip A. ; Wolin, Edward M. ; Cherepanov, Dasha ; Broder, Michael S. / Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors. In: World Journal of Gastroenterology. 2015 ; Vol. 21, No. 8. pp. 2450-2459.
@article{f060836ff353414e818d9748f0d31f1e,
title = "Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors",
abstract = "AIM: To evaluate systemic treatment choices in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors (PNETs) and provide consensus treatment recommendations. METHODS: Systemic treatment options for pancreatic neuroendocrine tumors have expanded in recent years to include somatostatin analogs, angiogenesis inhibitors, inhibitors of mammalian target of rapamycin and cytotoxic agents. At this time, there is little data to guide treatment selection and sequence. We therefore assembled a panel of expert physicians to evaluate systemic treatment choices and provide consensus treatment recommendations. Treatment appropriateness ratings were collected using the RAND/UCLA modified Delphi process. After studying the literature, a multidisciplinary panel of 10 physicians assessed the appropriateness of various medical treatment scenarios on a 1-9 scale. Ratings were done both before and after an extended discussion of the evidence. Quantitative measurements of agreement were made and consensus statements developed from the second round ratings. RESULTS: Specialties represented were medical and surgical oncology, interventional radiology, and gastroenterology. Panelists had practiced for a mean of 15.5 years (range: 6-33). Among 202 rated scenarios, disagreement decreased from 13.2{\%} (26 scenarios) before the face-to-face discussion of evidence to 1{\%} (2) after. In the final ratings, 46.5{\%} (94 scenarios) were rated inappropriate, 21.8{\%} (44) were uncertain, and 30.7{\%} (62) were appropriate. Consensus statements from the scenarios included: (1) it is appropriate to use somatostatin analogs as first line therapy in patients with hormonally functional tumors and may be appropriate in patients who are asymptomatic; (2) it is appropriate to use everolimus, sunitinib, or cytotoxic chemotherapy therapy as first line therapy in patients with symptomatic or progressive tumors; and (3) beyond first line, these same agents can be used. In patients with uncontrolled secretory symptoms, octreotide LAR doses can be titrated up to 60 mg every 4 wk or up to 40 mg every 3 or 4 wk. CONCLUSION: Using the Delphi process allowed physician experts to systematically obtain a consensus on the appropriateness of a variety of medical therapies in patients with PNETs.",
keywords = "Consensus, Delphi technique, Expert testimony, Grade 1, Grade 2, Intermediate tumors, Low tumors, Neuroendocrine carcinomas, Neuroendocrine tumors, Pancreatic neoplasms, Treatment, Unresectable, Well-differentiated",
author = "Strosberg, {Jonathan R.} and Fisher, {George A.} and Benson, {Al B.} and Anthony, {Lowell B.} and Bulent Arslan and Gibbs, {John F.} and Edward Greeno and Iyer, {Renuka V.} and Kim, {Michelle K.} and Maples, {William J.} and Philip, {Philip A.} and Wolin, {Edward M.} and Dasha Cherepanov and Broder, {Michael S.}",
year = "2015",
month = "2",
day = "28",
doi = "10.3748/wjg.v21.i8.2450",
language = "English (US)",
volume = "21",
pages = "2450--2459",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "8",

}

TY - JOUR

T1 - Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors

AU - Strosberg, Jonathan R.

AU - Fisher, George A.

AU - Benson, Al B.

AU - Anthony, Lowell B.

AU - Arslan, Bulent

AU - Gibbs, John F.

AU - Greeno, Edward

AU - Iyer, Renuka V.

AU - Kim, Michelle K.

AU - Maples, William J.

AU - Philip, Philip A.

AU - Wolin, Edward M.

AU - Cherepanov, Dasha

AU - Broder, Michael S.

PY - 2015/2/28

Y1 - 2015/2/28

N2 - AIM: To evaluate systemic treatment choices in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors (PNETs) and provide consensus treatment recommendations. METHODS: Systemic treatment options for pancreatic neuroendocrine tumors have expanded in recent years to include somatostatin analogs, angiogenesis inhibitors, inhibitors of mammalian target of rapamycin and cytotoxic agents. At this time, there is little data to guide treatment selection and sequence. We therefore assembled a panel of expert physicians to evaluate systemic treatment choices and provide consensus treatment recommendations. Treatment appropriateness ratings were collected using the RAND/UCLA modified Delphi process. After studying the literature, a multidisciplinary panel of 10 physicians assessed the appropriateness of various medical treatment scenarios on a 1-9 scale. Ratings were done both before and after an extended discussion of the evidence. Quantitative measurements of agreement were made and consensus statements developed from the second round ratings. RESULTS: Specialties represented were medical and surgical oncology, interventional radiology, and gastroenterology. Panelists had practiced for a mean of 15.5 years (range: 6-33). Among 202 rated scenarios, disagreement decreased from 13.2% (26 scenarios) before the face-to-face discussion of evidence to 1% (2) after. In the final ratings, 46.5% (94 scenarios) were rated inappropriate, 21.8% (44) were uncertain, and 30.7% (62) were appropriate. Consensus statements from the scenarios included: (1) it is appropriate to use somatostatin analogs as first line therapy in patients with hormonally functional tumors and may be appropriate in patients who are asymptomatic; (2) it is appropriate to use everolimus, sunitinib, or cytotoxic chemotherapy therapy as first line therapy in patients with symptomatic or progressive tumors; and (3) beyond first line, these same agents can be used. In patients with uncontrolled secretory symptoms, octreotide LAR doses can be titrated up to 60 mg every 4 wk or up to 40 mg every 3 or 4 wk. CONCLUSION: Using the Delphi process allowed physician experts to systematically obtain a consensus on the appropriateness of a variety of medical therapies in patients with PNETs.

AB - AIM: To evaluate systemic treatment choices in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors (PNETs) and provide consensus treatment recommendations. METHODS: Systemic treatment options for pancreatic neuroendocrine tumors have expanded in recent years to include somatostatin analogs, angiogenesis inhibitors, inhibitors of mammalian target of rapamycin and cytotoxic agents. At this time, there is little data to guide treatment selection and sequence. We therefore assembled a panel of expert physicians to evaluate systemic treatment choices and provide consensus treatment recommendations. Treatment appropriateness ratings were collected using the RAND/UCLA modified Delphi process. After studying the literature, a multidisciplinary panel of 10 physicians assessed the appropriateness of various medical treatment scenarios on a 1-9 scale. Ratings were done both before and after an extended discussion of the evidence. Quantitative measurements of agreement were made and consensus statements developed from the second round ratings. RESULTS: Specialties represented were medical and surgical oncology, interventional radiology, and gastroenterology. Panelists had practiced for a mean of 15.5 years (range: 6-33). Among 202 rated scenarios, disagreement decreased from 13.2% (26 scenarios) before the face-to-face discussion of evidence to 1% (2) after. In the final ratings, 46.5% (94 scenarios) were rated inappropriate, 21.8% (44) were uncertain, and 30.7% (62) were appropriate. Consensus statements from the scenarios included: (1) it is appropriate to use somatostatin analogs as first line therapy in patients with hormonally functional tumors and may be appropriate in patients who are asymptomatic; (2) it is appropriate to use everolimus, sunitinib, or cytotoxic chemotherapy therapy as first line therapy in patients with symptomatic or progressive tumors; and (3) beyond first line, these same agents can be used. In patients with uncontrolled secretory symptoms, octreotide LAR doses can be titrated up to 60 mg every 4 wk or up to 40 mg every 3 or 4 wk. CONCLUSION: Using the Delphi process allowed physician experts to systematically obtain a consensus on the appropriateness of a variety of medical therapies in patients with PNETs.

KW - Consensus

KW - Delphi technique

KW - Expert testimony

KW - Grade 1

KW - Grade 2

KW - Intermediate tumors

KW - Low tumors

KW - Neuroendocrine carcinomas

KW - Neuroendocrine tumors

KW - Pancreatic neoplasms

KW - Treatment

KW - Unresectable

KW - Well-differentiated

UR - http://www.scopus.com/inward/record.url?scp=84923804019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923804019&partnerID=8YFLogxK

U2 - 10.3748/wjg.v21.i8.2450

DO - 10.3748/wjg.v21.i8.2450

M3 - Article

VL - 21

SP - 2450

EP - 2459

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 8

ER -